Parasym Health

Executive Summary

Parasym Health is a UK-based digital health and neuroscience company developing a clinically proven, patented wearable neuromodulation device that targets the vagus nerve to deliver therapeutic benefits. Founded in 2017, the company aims to advance human health and performance by modulating neural communication pathways. Its device is designed for non-invasive vagus nerve stimulation (nVNS), addressing conditions such as anxiety, depression, chronic pain, and stress-related disorders. With a growing body of clinical evidence supporting its efficacy, Parasym Health is positioned in the rapidly expanding neuromodulation market, which is driven by increasing demand for non-pharmacological interventions and digital therapeutics. The company has commercialized its device in certain markets, but as a private firm with limited disclosed funding, it likely relies on revenue from sales and possibly grant support. Key challenges include navigating regulatory pathways (e.g., FDA clearance for the US market), scaling manufacturing, and competing with established players like electroCore and NeuroSigma. However, Parasym's focus on a proprietary, user-friendly wearable could differentiate it. The company's future growth depends on expanding clinical indications, securing distribution partnerships, and raising capital to fuel commercialization efforts.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) Clearance for Expanded Indications50% success
• Q4 2026Publication of Phase II Clinical Trial Results in Major Depression70% success
• Q3 2026Series A Funding Round or Strategic Partnership60% success